Ameritas Advisory Services’s Xenon Pharmaceuticals XENE Stock Holding History

Ameritas Advisory Services’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.11K	Buy	+35	New	+$1.94K	﹤0.01%	1690

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Ameritas Advisory Services's XENE Position: Q2 2026 in Review

Ameritas Advisory Services opened a new position in Xenon Pharmaceuticals (XENE) in Q2 2026: 35 shares worth $2.11K. The stake represents ﹤0.01% of the portfolio and ranks #1690 among its holdings.

315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Ameritas Advisory Services held 35 shares of Xenon Pharmaceuticals worth $2.11K as of Q2 2026.
Xenon Pharmaceuticals was a new Ameritas Advisory Services position in Q2 2026.
Xenon Pharmaceuticals made up ﹤0.01% of Ameritas Advisory Services's portfolio in Q2 2026, its #1690 holding.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Ameritas Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.